Tehran University of Medical Sciences Current Journal of Neurology 2717-011X 17 3 2018 07 05 129 136 EN Seyed Mohammad Baghbanian Bualicina Hospital, Mazandaran University of Medical sciences, Sari, Iran Mohammad Ali Sahraian Multiple Sclerosis Research Centre, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran 2017 05 31 2018 04 28 Interferon beta (IFN-β) and glatiramer acetate (GA) are the primary therapeutic immunomodulatory agents that interfere with relapsing-remitting multiple sclerosis (RRMS), and the most commonly-used drugs as well. Induction or aggravation of other immune-mediated diseases has been reported following INF-β administration. We have reviewed the reported cases to notify the treating physicians about these rare adverse events. Although co-morbid autoimmune disorders have been reported in patients with MS, the pro-inflammatory role of disease-modifying drugs, especially INF-β, could affect and enhance this co-occurrence. Clinical or laboratory autoimmunity histories suggest the use of GA over INF-β as the treatment of choice. https://ijnl.tums.ac.ir/index.php/ijnl/article/view/1325